# Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses

> **NCT02254993** · PHASE2 · COMPLETED · sponsor: **Armata Pharmaceuticals, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Dental Caries

## Interventions

- **DRUG:** C16G2

## Key facts

- **NCT ID:** NCT02254993
- **Lead sponsor:** Armata Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-06
- **Final completion:** 2015-07
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2019-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254993, "Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02254993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*